The future of agile AI biotherapeutic discovery
LENSai™ Uniting In Silico, In Vitro and In Vivo Discovery
Step into the future of biotherapeutic discovery with LENSai. Our powerful technology is at the forefront of healthcare innovation, accelerating drug discovery through scalable data visualization and insights. Integrating in silico, in vitro and in vivo analyses to create a hub of biotherapeutic intelligence. This state-of-the-art approach enables rapid identification of novel therapeutic targets and potentially enhances drug efficacy with reduced side effects. This opens the door to the creation of life-changing drug candidates that have the potential to transform patients’ lives in meaningful ways. Join us in creating innovative solutions where none have previously existed.
Engineered for acceleration
Engineered for the undiscovered
Efficient In Vitro, In Vivo and In Silico antibody discovery and validation streamline the path to clinic.
Breaking new ground: solving antibody discovery for complex targets
Unparalleled pan-omic insight: smarter by the second
Cracking the code: big data with unprecedented insight and analysis
Of druggable proteins are targeted by FDA‑approved drugs*
Unique antibody production by the human body*
2023 market growth rate of AI in drug discovery*